natalizumab   Click here for help

GtoPdb Ligand ID: 6591

Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Approved drug Immunopharmacology Ligand
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases. It targets α4β1 integrin (VLA-4) on leukocytes to block interaction with vascular cell adhesion molecule 1 (VCAM-1) on inflamed endothelium, thus inhibiting leukocyte extravasation into sites of inflammation. It is active in peripheral tissues and the central vervous system.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a valid approach for the development of novel anti-inflammatory therapeutics [3]. The design and synthesis of this antibody was originally described in a 1997 publication [2].

The first natalizumab biosimilar was approved by the FDA in August 2023. Like the originator/reference agent, Tyruko® (natalizumab-sztn; Sandoz Inc.) is indicated for relapsing forms of multiple sclerosis and moderate-severe active Crohn's disease (when conventional therapies, including TNF-α inhibitors, are inadequate or not tolerated).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: natalizumab

Bioactivity Comments
We have been unable to find affinity data for this antibody from an open access article.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor) Primary target of this compound Hs Antibody Inhibition - - - 4
integrin α4β1 Hs Antibody Inhibition - - - 4
Ligand mentioned in the following text fields